Who are Cullinan Therapeutics, Inc.'s main suppliers?

Cullinan Therapeutics, Inc. (CGEM) key suppliers include: CONTRACT-MANUFACTURING-ORGANIZATIONS, CONTRACT-RESEARCH-ORGANIZATIONS, VENDORS, ArriVent BioPharma, Inc., Climb Bio, Inc. and 2 more. View the full supplier network at chainsifter.com/chain/CGEM.

Who are Cullinan Therapeutics, Inc.'s major customers?

Cullinan Therapeutics, Inc. (CGEM) key customers include: TAIHO, TAIHO-AFFILIATE, Fate Therapeutics, Inc., IN8bio, Inc., USA-LLC. View the full customer network at chainsifter.com/chain/CGEM.

What sector is Cullinan Therapeutics, Inc. in?

Cullinan Therapeutics, Inc. (CGEM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Cullinan Therapeutics, Inc. Supplier List (CGEM): 7 Verified Suppliers

7Suppliers

5Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Cullinan Therapeutics, Inc. (CGEM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

1Distinct source URLs

8High confidence

0.806Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Cullinan Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS	CONTRACT-MANUFACTURING-ORGANIZATIONS	90%	The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies…
CONTRACT-RESEARCH-ORGANIZATIONS	CONTRACT-RESEARCH-ORGANIZATIONS	90%	The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies…
VENDORS	VENDORS	85%	In addition, we enter into agreements in the normal course of business with CROs for clinical trials and with other vendors for preclinical studies, manufacturing services, and other services and pro…
AVBP	ArriVent BioPharma, Inc.	72%	Reciprocal relationship from AVBP graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from AVBP graph: therwise prefer to develop and market ourselves. We also face substantial co…
CLYM	Climb Bio, Inc.	72%	Reciprocal relationship from CLYM graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product ca…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from INAB graph: Reciprocal relationship from CGEM graph: Reciprocal relationship from INAB g…

Cullinan Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TAIHO	TAIHO	90%	We have received $275.0 million in revenue from a previous license agreement and cash proceeds of $18.9 million from the sale of our equity interest in our former zipalertinib development subsidiary …
TAIHO-AFFILIATE	TAIHO-AFFILIATE	90%	Pursuant to our co-development agreement, we are collaborating with a Taiho affiliate to develop zipalertinib for the treatment of a genetically defined subset of patients with NSCLC, and Taiho will …
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adve…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
USA-LLC	USA-LLC	62%	ment obligations — 38 Equity-based compensation 3,959 3,929 Total research and development expenses $ 42,123 $ 41,459 The $0.7 million increase in research and development expenses in the three month…

Cullinan Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CGEM-DEBT	Debt stack $2.4M	90%	Market cache reports total debt of $2.4M.
CGEM-DEBT-8611	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-09-30.

Cullinan Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CGEM-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP	Lynx1 Capital Management LP	90%	13F overlay lists Lynx1 Capital Management LP as top holder; 174 tracked holders.

Cullinan Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
INAB	IN8bio, Inc.	100.00	1	['customer', 'supplier']
BDTX	Black Diamond Therapeutics, Inc.	100.00	2
JBIO	Jade Biosciences, Inc.	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	1	['customer', 'supplier']
VERA	Vera Therapeutics, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
RCUS	Arcus Biosciences, Inc.	100.00	2
JNJ	Johnson & Johnson	100.00	2
KYTX	Kyverna Therapeutics, Inc.	100.00	2
ALMS	Alumis Inc.	100.00	2
VRTX	Vertex Pharmaceuticals Incorporated	100.00	2
ZBIO	Zenas BioPharma, Inc.	100.00	2
TAIHO	TAIHO	60.75	1	['receiving']
STTK	Shattuck Labs, Inc.	50.00	2
LEPU	LEPU	50.00	2
ALLIST	ALLIST	50.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	50.00	2
EDIT	Editas Medicine, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2

Cullinan Therapeutics, Inc. Supply Chain